Establishment Labs (ESTA) to Release Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Establishment Labs to announce earnings of ($0.34) per share and revenue of $65.7910 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The company had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business’s revenue was up 44.7% on a year-over-year basis. During the same period last year, the firm posted ($0.70) earnings per share. On average, analysts expect Establishment Labs to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Establishment Labs Stock Up 0.0%

NASDAQ ESTA opened at $91.93 on Thursday. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. Establishment Labs has a fifty-two week low of $33.35 and a fifty-two week high of $96.99. The business has a 50 day moving average price of $84.07 and a two-hundred day moving average price of $73.22. The stock has a market cap of $2.71 billion, a PE ratio of -61.70 and a beta of 1.06.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ESTA shares. Citigroup boosted their target price on shares of Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. BTIG Research reissued a “buy” rating on shares of Establishment Labs in a research report on Monday, July 13th. Finally, Mizuho raised their target price on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $90.43.

Insiders Place Their Bets

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 180,000 shares of company stock worth $13,225,275. 9.99% of the stock is owned by company insiders.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds have recently bought and sold shares of ESTA. Geode Capital Management LLC raised its stake in Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after buying an additional 299 shares in the last quarter. Swiss National Bank grew its position in shares of Establishment Labs by 1.8% in the 4th quarter. Swiss National Bank now owns 34,200 shares of the company’s stock worth $2,492,000 after acquiring an additional 600 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Establishment Labs in the 4th quarter valued at approximately $47,000. Private Advisor Group LLC raised its position in shares of Establishment Labs by 14.1% during the 3rd quarter. Private Advisor Group LLC now owns 5,450 shares of the company’s stock valued at $223,000 after acquiring an additional 675 shares in the last quarter. Finally, Quarry LP bought a new position in Establishment Labs during the third quarter worth $34,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.